Mabwell Signs Exclusive License Agreement with Qilu Pharma for Albipagrastim alfa Injection Mabwell has entered into a significant agreement with Qilu Pharmaceutical for the development and commercialization of Albipagrastim alfa in Greater China. The deal is a major step in enhancing cancer treatment efficacy.

Mabwell Signs Exclusive License Agreement with Qilu Pharma for Albipagrastim alfa Injection #China #Shanghai #Mabwell #Albipagrastim #Qilu_Pharma